WO2004053071A9 - Method for discovering neurogenic agents - Google Patents

Method for discovering neurogenic agents Download PDF

Info

Publication number
WO2004053071A9
WO2004053071A9 PCT/US2003/038670 US0338670W WO2004053071A9 WO 2004053071 A9 WO2004053071 A9 WO 2004053071A9 US 0338670 W US0338670 W US 0338670W WO 2004053071 A9 WO2004053071 A9 WO 2004053071A9
Authority
WO
WIPO (PCT)
Prior art keywords
neurogenesis
neurons
neural progenitor
vol
kelleher
Prior art date
Application number
PCT/US2003/038670
Other languages
French (fr)
Other versions
WO2004053071A3 (en
WO2004053071A2 (en
Inventor
Judith Kelleher-Andersson
Karl K. Johe
Original Assignee
Judith Kelleher-Andersson
Johe Karl K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Judith Kelleher-Andersson, Johe Karl K filed Critical Judith Kelleher-Andersson
Priority to AU2003293409A priority Critical patent/AU2003293409A1/en
Priority to EP03790356A priority patent/EP1576134B1/en
Publication of WO2004053071A2 publication Critical patent/WO2004053071A2/en
Publication of WO2004053071A3 publication Critical patent/WO2004053071A3/en
Publication of WO2004053071A9 publication Critical patent/WO2004053071A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Definitions

  • bromodeoxyuridine (BrdU) and by immunostaining of postmortem brains with antibo ; dies against BrdU and neuronal markers.
  • An endogenous marker of dividing cells ki67 protein, has also been used instead of BrdU for this PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL . purpose.
  • the location of neurogenic areas in the CNS is limited to the dentate gyrus of the hippocampus and the subependymal layer of the striatum.
  • BrdU has revealed significant number of new cells and new neurons being born in the dentate gyrus and the subependymal layer of the striatum.
  • the process of generating new neurons occurs in the mature, adult brain in significant quantities throughout rodents, primates, and human species.
  • Hippocampus is the well-known center of learning, memory, and other cognitive functions, processes which new information are added, edited, stored, and recalled constantly throughout life.
  • neurogenesis becomes more widespread and perhaps functionally diverse.
  • the newly born neurons of the subependyma also referred to as subventricular zone
  • the newly born neurons have short survival period.
  • a compound that can stimulate the endogenous neurogenesis either in a disease state or in a healthy PCT PATENT APPLICATION OF KELLEHER -ANDERS SON ET AL . state may be an effective drug for a number of human nervous system diseases.
  • the current limitation is the lack of an effective., predictive in vitro assay that can be used to select a neurogenic compound for clinical drug development.
  • a novel, in vitro assay which is effective and predictive, to be useful for discovering a compound that promotes neurogenesis in vivo.
  • classes of compound structures that are shown to be particularly effective in promoting the
  • This invention relates to the method of discovering a neurogenic drug to treat neurologic, psychiatric, and aging-related disorders. It also relates to the use of Fused Imidazoles/, Aminopyrimidines , Nicotinamides,
  • Phenoxypiperidines and Aryloxypiperidines for use as therapeutic agents and analytical reagents by means of promoting neurogenesis. More particularly this invention relates to these agents as therapeutics for prevention and treatment of neurological diseases in mammals and reagents for detecting neurogenesis and proliferation.
  • SSRIs selective serotonin uptake inhibitors
  • fluoxetine the mixed noradrenaline/serotonin transporter blockers like tricyclic agent imipramine and noradrenaline uptake inhibitors like desipramine.
  • the antidepressant- induced increase in -intraneuronal biogenic amines occurs quite rapidly.
  • hippocampal volume loss might be considered a consequence of glucocorticoid-induced hippocampal neuronal loss
  • Neurogenesis can be characterized as three successive stages: proliferation of endogenous stem cells and
  • depression could potentially be caused by 1) inhibition of the endogenous hippocampal stem cell proliferation in the dentate gyrus, 2) inhibition of differentiation and PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . dendrite development and 3) by loss of neurons (apoptosis) and their dendritic structure.
  • apoptosis is observed in depression, hippocampal apoptosis as measured by DNA fragmentation from depressed patients appears to play only a minor role in the volume loss (Lucassen et al., 2001).
  • the stress did cause a reduction in synaptic plasticity in the hippocampus (Xu et al., 1998).
  • imipramine partially reversed the loss in LTP in socially stressed, depressive-like animals (Von Frijtag et al.,. 2001) suggesting imipramine effects on the plasticity phase of neurogenesis.
  • Another animal model of depression presenting neurogenesis loss and hippocampal volume loss, stressed animals that chronically received the antidepressant, tianeptine, showed similar numbers of dividing cells as control animals (no social stress) a measure of proliferation (Czeh et al . , 2001).
  • hippocampal dentate gyrus (Gould et al., 2001; Eriksson et al., 1998), we can use multi-potential hippocampal stem cells to screen agents in vitro for neurogenic activity.
  • phosphorylated CREB then binds to CRE binding site to promote the expression of BDNF and bcl—2, that 1 appear critical to cell survival and plasticity. Proof of
  • neurotrophic factor BDNF' s involvement in depression comes from studies showing that antidepressants and
  • electroconvulsive shock both caused an increase in BDNF levels (Nibuya et al., 1996) and that intrahippocampal injection of BDNF had antidepressant activity in two models of depression (Shirayama et al . , 2002) .
  • AD therapeutics that address the neuronal loss, in the hopes of reducing the cognitive decline.
  • One strategy enlists trophic agents, that regulate neuronal function and survival, as AD therapeutics (see Peterson and Gage, 1999) . Problems with systemic administration, side effects and locating trophic- sensitive neurons generated few clinical successes with these therapies.
  • One AD therapeutic, AIT-082 promotes memory enhancement in AD individuals potentially by stimulating endogenous trophic factors (Ritzman and Glasky, 1999;
  • Hippocampus is one of the main brain regions where neurogenesis in adult brain has been documented across several vertebrate species, including monkeys and humans (e.g., Gould et al., 2001; Eriksson et al., 1998). In fact, adult
  • hippocampal neurogenesis contributes functionally to cognitive capacity.
  • Shors et al. 2001
  • inhibition of PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL neurogenesis in adult rat hippocampus, in the absence of the destruction of existing neurons, caused impaired memory function.
  • a focal ischemic model reversible photothrombic ring stroke, caused increased neurogenesis in rat cortex by 3- 6% (Gu et al . , 2000). Seizures induced by electroconvulsive shock in adult rats increased neurogenesis in dentate gyrus of hippocampus (Scott et al, 2000; Madsen et al, 2000). Also, rats gamma-irradiated to kill mitotic cells in the CNS showed reduced numbers of nascent neurons and reduced LTP in slice cultures. These observations highlight the likelihood that a cellular mechanism for neurogenesis within adult human CNS, especially in hippocampus, does exist both as a normal
  • a small molecule that induces hippocampal neurogenesis that is blood brain barrier penetrable would allow for a potentially novel oral therapeutic for Alzheimer's disease.
  • AD therapeutics progressing in clinical trials, target neurodegeneration in the hopes of reducing the neuronal loss and cognitive decline.
  • Apoptotic death involving caspase pathways and DNA fragmentation has been measured in in vitro and animal models of AD and in Alzheimer's diseased brain tissue.
  • the extent of apoptosis leading to neuronal loss is of continual debate with most agreeing it has some effect, but that other neuronal death pathways definitely play a role PCT PATENT APPLICATION OF KELLEHE - NDERS SON ET AL .
  • neuroprotective agents may improve or reverse the cognitive decline observed in MCI and AD.
  • neurogenesis in a mammalian neuroepithelium proliferation and differentiation of an olfactory neuron precursor in vitro.
  • Opioids intrinsically inhibit the genesis of mouse cerebellar granule neuron precursors in vitro: differential impact of mu and delta receptor activation on proliferation and neurite elongation. Eur J Neurosci. vol 12 ( ): 1281-93.
  • VEGF Vascular endothelial growth factor
  • Intracerebroventricular infusion of insulin-like growth factor-1 ameliorates the age-related decline in hippocampal neurogenesis. Neuroscience vol. 107 (4), pp603-613.
  • Acetylcholine stimulates cortical precursor cell proliferation in vitro via
  • CREB cAMP response element binding protein
  • Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. J Neurosci. vol 19 (19) : 8487-97.
  • Rathbone MP Middlemiss PJ, Gysbers J , Andrew C, Herman MA, Reed JK, Ciccarelli R, Di Iorio P, and Caciagli F.
  • hippocampal progenitor cells in vitro temporal expression of intercellular coupling and voltage- and ligand-gated responses.
  • FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor. Neuron, vol 28 (2 ): 385-97.
  • Glucocorticoid receptor and protein/RNA synthesis-dependent mechanisms underlie the control of synaptic plasticity by stress. PNAS USA. vol 95:3204-3208.
  • a neurogenic drug is an agent that enhances the process of generating new neurons (neurogenesis) . Recent studies indicate that neurogenesis occurs in the adult human brains under normal as well as under degenerative conditions and that such adult-generated neurons do
  • Neurodegenerative conditions including Alzheimer's disease, mild cognitive impairment, dementia, age-related cognitive decline, stroke, traumatic brain injury, spinal cord injury and the like are neurodegenerative conditions.
  • Neuropsychiatric diseases including depression, anxiety, schizophrenia and the like also show nerve cell
  • a neurogenic drug would be beneficial for countering and treating these diseases.
  • the present invention discloses a method of
  • Such drug will serve to prevent or treat neurodegenerative and neuropsychiatric disorders by promoting the birth of new neuron endogenously within the nervous system by administering the compounds of the present invention into the patient. This may involve delivery of the agents alone or together with transplanted stem cells or progenitor cells.
  • compounds of the type Fused Imidazoles, Aminopyrimidines , Nicotinamides, Aminomethyl Phenoxypiperidines and Aryloxypiperidines are evaluated for their ability to promote neurogenesis by proliferation/ differentiation of human hippocampal multipotent stem/ progenitor cells and neuronal progenitors.
  • Figure 1 Schematic description of neurogenesis processes captured in the assay and different potential sites of a neurogenic drug action.
  • Alamar Blue a fluorescent dye, is used as an indicator of metabolic respiration to determine optimum plating density. Results at an initial plating density of 30,000 cells/well suggest a large difference in cell number on removal of mitogen from the N2b media
  • Figure 3A Influence of known growth factors on proliferation and neurogenesis relative to control.
  • Hippocampal progenitor cells were treated for seven days with differentiation media (without mitogen) in the
  • Hippocampal progenitor cells were treated for seven days with differentiation media (without mitogen) in the
  • the percentage of neurons calculated for each treatment are as follows: 48.5 + 6.3% for controls and 53.6+1.15 for LIF.
  • the non-TUJl positive cells are mainly astrocytic (GFAP+) .
  • Figure 4 Examples of proliferation profile of compounds selected from primary screening. Proliferation was measured after compound treatment for 7 days by Alamar Blue staining of live cells per well. Shown are relative values over the vehicle control.
  • Typical ratio for vehicle control is 40-50% neurons. The ratio can change by either increased
  • a screening of a large number of unknown agents e.g., protein factors, peptides, nucleic acids, natural
  • a neural progenitor population derived as a stable cell line from partial differentiation of embryonic stem cells can also be used.
  • a cell line is defined as a population of cells having been expanded for at least 10 cell-doublings.
  • Cell lines that are genetically engineered to enhance the cells' mitotic capacity can also be used.
  • the genetic modification consists of over-expression of functional c-myc protein intracellularly under a conditional activation system such as c-myc protein fused to a ligand-binding domain of an estrogen receptor.
  • a conditional activation system such as c-myc protein fused to a ligand-binding domain of an estrogen receptor.
  • a progenitor population that upon differentiation generates both neurons and glia in a single culture has been used. Presence of glia, either astrocytes and/or oligodendrocytes or their
  • differentiation of the progenitors is initiated by withdrawing the mitogen from the culture. Serum as well as other growth-promoting factors should be avoided from the differentiating culture since they will significantly affect the reproducibility and interfere with the neurogenesis assay.
  • Undifferentiated mitotic cells are harvested by enzyme treatment to remove residual mitogen, in the preferred embodiment, basic fibroblast growth factor (bFGF) .
  • bFGF basic fibroblast growth factor
  • the initial seeding density can be within the range of about 2,000-125,000 cells per well of a 96-well plate.
  • the preferred density is 40,000 cells per well of a 96-well plate, which has been optimized for best signal-to-noise ratio. Too low cell density retards the initiation of differentiation and results in poor plating efficiency, PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . which interferes with the assay. Too high cell density leads to inhibition of neurogenesis due to cell-cell contact and paracrine factors, which also interferes with the assay.
  • the actual cell number can be proportionally decreased or increased depending upon the surface area of the culture substrate used. For example, for a 384-well plate, which has approximately 1/4 of the surface area of a 96-well plate, the initial seeding density should be decreased accordingly (1/4).
  • a neurogenic drug is to increase the number of neurons generated from their precursors.
  • a molecule can bring about such increase in the neurogenesis by a number of different mechanisms. It can act as a mitogen for the neural stem/progenitor cells and increase the progenitor's cell number, which in turn results in increased number of neurons in the culture when
  • PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL it can act as a mitogen for committed neuronal progenitors that differentiate only into neurons. Increasing this subpopulation would also increase the final number of neurons in the culture. Or, it can act as a survival factor to rescue immature neurons from undergoing cell death during differentiation, which will result in
  • the assay method here captures all of these
  • the assay is continued for seven days. A minimum of three days from the onset of differentiation should be allowed for stable expression of definitive neuronal markers to appear. A sufficient time is also required for a compound action on differentiation and/or proliferation to take place to a sufficient degree to be reliably detectable. Manifestation of drug-induced changes in neuron number takes a minimum of three days for the human cells to be detectable.
  • the final neuron number is detected by immunostaining of the culture with antibodies against neurons and
  • the collected cells were seeded at 40,000 cells per well of 96-well plates pre-coated with extracellular matrix proteins (e.g., Biocoat PDL, Fisher).
  • the seeding media is a standard serum-free, growth factor- free, basal media that supports healthy neuronal/glial survival, such as N2 without phenol red.
  • the fluorescence level is proportional to the number of respiring cells in the culture and is a measure of a proliferative activity of a test agent ( Figure 2) .
  • the cells were fixed and stained with antibodies against neuron-specific antigens according to standard procedures.
  • Typical antigens effective were Typelll-beta tubulin and
  • the total cell number in each well was quantified by staining the cultures with a nuclear dye such as DAPI or Hoechst according to standard procedures.
  • Example 1 Selection of a positive control.
  • Several neurotrophic factors--including brain-derived neurotrophic factor, glia-derived neurotrophic factor, neurotrophic PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL . factor-3, and leukemia inhibitory factor--suggested to have neurogenic properties were tested in the assay described above. Only one (leukemia inhibitory factor) was effective ( Figure 3A and 3B) . Thus, the assay can discriminate test agents for selectively having a neurogenic activity.
  • the positive control utilized is leukemia inhibitory factor (LIF) , a cytokine growth factor, at 20 ng/ml.
  • LIF leukemia inhibitory factor
  • LIF as the positive control is based on its properties to increase by 2-3 fold the number of neurons and glia. This effect validates both the neural stem cell system, in which, should a compound be effective in neurogenesis, the cells respond appropriately by enhanced differentiation and/or mitosis, and the assay method in which such cellular responses can be measured reproducibly and quantifiably .
  • Example 2. Primary screening of unknown compounds.
  • Imidazoles, Aminopyrimidines , Nicotinamides, Aminomethyl Phenoxypiperidines and Aryloxypiperidines are evaluated for their effect on neurogenesis according the assay method described above. From the preliminary analysis using the fluorescent plate reader, over 300 compounds to date showed initial positive activity. Those were re-analyzed by quantitative neuron counting. Among them, 30 compounds PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . significantly increased cell number '( "proliferation" ,
  • Table II contains the summary of EC50 of each compound tested. On the other hand, at high
  • an agent would be administered to treat a neurodegenerative disease.
  • the agent would be administered to treat a neurodegenerative disease.
  • neurodegenerative disease would be Alzheimer's disease, dementia, mild cognitive impairment, aged-related cognitive decline, Parkinson's disease, amyotrophic lateral
  • sclerosis multiple sclerosis, demyelination, stroke, spinal injuries, traumatic injuries, neuropathic pain, and the like.
  • this invention would be administered to treat a psychiatric disease.
  • the psychiatric disease is depression, post-traumatic stress syndrome, stress, anxiety, schizophrenia, sleep deprivation, cogntive dysfunction, amnesia, and the like.
  • an agent would be administered by any number of routes and multipotent stem cells or differentiated multipotent stem cells would be transplanted into brain.

Abstract

A method for discovering neurogenic drugs is revealed. The method allows for systematic screening of test agents such as libraries of compounds. The method consists of exposing test agents to cultures of differentiating neural progenitor cells and measuring their effects on increasing the overall cell number and/or the number of neurons.

Description

METHOD FOR DISCOVERING NEUROGENIC AGENTS
The present patent application claims the benefit of U.S. Provisional Patent Application 60/432,359, filed December 9, 2002, and U.S. Provisional Patent Application 60/493,674, filed August 8, 2003, which are hereby incorporated by reference in their entirety and relied upon .
BACKGROUND OF THE INVENTION
1. FIELD OF THE INVENTION
According to a long-held doctrine, no significant number of neurons are made and contribute to function in the adult mammalian nervous system. However, recent data indicate that adult mammalian brains contain neural precursor cells capable of generating new neurons both in normal and in injured conditions. These new neurons have been quantified in live animals by injecting or feeding in drinking water a marker of dividing cells,
bromodeoxyuridine (BrdU) and by immunostaining of postmortem brains with antibo;dies against BrdU and neuronal markers. An endogenous marker of dividing cells, ki67 protein, has also been used instead of BrdU for this PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL . purpose. Thus, in healthy, young rodents, approximately 3,000 - 15,000 new cells per day are estimated to be born in the dentate gyrus of the hippocampus, about 60% of which express early neuron-specific proteins such as double- cortin and type III beta-tubulin . Significant number of new cells and new neurons have also been observed in healthy, young primates. In rodents as well as in
primates, the location of neurogenic areas in the CNS is limited to the dentate gyrus of the hippocampus and the subependymal layer of the striatum. In human patients of different ages who have been diagnosed with a tumor of the tongue, a single injection of BrdU has revealed significant number of new cells and new neurons being born in the dentate gyrus and the subependymal layer of the striatum. Thus, the process of generating new neurons (neurogenesis) occurs in the mature, adult brain in significant quantities throughout rodents, primates, and human species.
Such significant quantities of new neurons suggest that they may be important for the normal physiology of the brain, especially the hippocampus. Hippocampus is the well-known center of learning, memory, and other cognitive functions, processes which new information are added, edited, stored, and recalled constantly throughout life. PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Since hippocampus is also the most potent neurogenic area of the brain, many studies have been undertaken to*
establish whether neurogenesis may be the cellular
mechanism to structurally , accommodate the ever-increasing volume of cognitive processing to be handled. Thus, it has been shown that at least some of the newly born neurons, marked by genetic markers, do mature to be
electrophysiologically active and integrate into the existing neuronal circuitry of the hippocampus. Ablation of the neurogenesis in rats leads to decreased cognitive capabilities in several behavior tests. Thus, the existing data demonstrate that neurogenesis significantly
contributes to the normal hippocampal physiology.
In abnormal conditions, such as when an injury to a brain area has occurred, neurogenesis becomes more widespread and perhaps functionally diverse. In rodent models of ischemic and hemorrhagic stroke, the newly born neurons of the subependyma (also referred to as subventricular zone) are seen migrating to and accumulating in the lesion area of the cortex. However, the newly born neurons have short survival period.
Thus, a compound that can stimulate the endogenous neurogenesis either in a disease state or in a healthy PCT PATENT APPLICATION OF KELLEHER -ANDERS SON ET AL . state may be an effective drug for a number of human nervous system diseases. However, the current limitation is the lack of an effective., predictive in vitro assay that can be used to select a neurogenic compound for clinical drug development. Disclosed here is a novel, in vitro assay, which is effective and predictive, to be useful for discovering a compound that promotes neurogenesis in vivo. Also disclosed are classes of compound structures that are shown to be particularly effective in promoting the
neurogenesis .
This invention relates to the method of discovering a neurogenic drug to treat neurologic, psychiatric, and aging-related disorders. It also relates to the use of Fused Imidazoles/, Aminopyrimidines , Nicotinamides,
Aminomethyl Phenoxypiperidines and Aryloxypiperidines for use as therapeutic agents and analytical reagents by means of promoting neurogenesis. More particularly this invention relates to these agents as therapeutics for prevention and treatment of neurological diseases in mammals and reagents for detecting neurogenesis and proliferation. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
2. DESCRIPTION OF THE RELATED ART
Most antidepressants are thought to work by increasing the levels of monoamines available for post-synaptic receptors. Examples of classes of agents working apparently by the "monoaminergic hypothesis of depression" include the selective serotonin uptake inhibitors (SSRIs) like
fluoxetine, the mixed noradrenaline/serotonin transporter blockers like tricyclic agent imipramine and noradrenaline uptake inhibitors like desipramine. The antidepressant- induced increase in -intraneuronal biogenic amines occurs quite rapidly. However, the antidepressant-induced
improvement in clinical behavior requires weeks of daily administration .
One hypothesis that may account for the slow-onset of the antidepressants' therapeutic activity is that they work by promoting hippocampal neurogenesis. It is expected that neurogenesis would require a number of weeks for stem cells to divide, differentiate, migrate and establish connections with post-synaptic neurons. The neurogenesis theory of depression then postulates that antidepressant effect is brought about by structural changes in the hippocampal circuitry contributed by newly generated neurons stimulated PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL . by antidepressants (Malberg et al . , 2000; Czeh et al, 2001; Santarelli et al, 2003) .
The neurogenic theory of depression, though not
conclusive, has strong supportive data including the finding that neurogenesis is actually requisite for
antidepressant behavioral improvement in the novelty suppressed feeding model (Santarelli et al., 2003) . A therapeutic benefit from hippocampal neurogenesis is further supported by the finding of hippocampal atrophy in depression, where MRI imaging studies identified a
reduction in the right and the left hippocampal volumes in individuals with major depression (Sheline et al., 1996; Bremner et al., 2000; Mervaala et al . , 2000). Long standing works also suggest a strong relationship between
glucocorticoid dysregulation or glucocorticoid
hypersecretion in stress and depression, such that the hippocampal volume loss might be considered a consequence of glucocorticoid-induced hippocampal neuronal loss
(Sheline et al., 1996; Lucassen et al. , 2001; Lee et al., 2002 (review)). Furthermore, in studies which involved the administration of a chronic stress to animals, both
hippocampal volume changes and reduction in neurogenesis were observed, and these events were both reversed by PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL . chronic antidepressant administration (Czeh et al., 2001; Pham et al., 2003), further illustrating the strong
association between depression, stress and neurogenesis. The association comes full circle, since agents or
conditions that promote a reduction in neurogenesis also appear as causative agents/events in depression,
specifically glucocorticoid (Sapolsky, 2000), and depletion of serotonin (Brezun and Daszuta, 1999). Kempermann and Kronenberg (2003) , though acknowledging the validity of the hippocampal neurogenesis theory of depression, suggest that this hypothesis needs to be looked at in the context of a larger model of cellular, plasticity, which elucidates ho antidepressants induce nascent neurons of unknown phenotype to survive and produce viable circuits.
Neurogenesis can be characterized as three successive stages: proliferation of endogenous stem cells and
precursors, differentiation into neurons and neuron
maturation with formation of viable synaptic connections (plasticity) . By taking into account all stages of
neurogenesis, then the hippocampal volume loss in
depression could potentially be caused by 1) inhibition of the endogenous hippocampal stem cell proliferation in the dentate gyrus, 2) inhibition of differentiation and PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . dendrite development and 3) by loss of neurons (apoptosis) and their dendritic structure. Though apoptosis is observed in depression, hippocampal apoptosis as measured by DNA fragmentation from depressed patients appears to play only a minor role in the volume loss (Lucassen et al., 2001). In an animal model of acute stress or in normal animals receiving exogenous corticosterone the stress did cause a reduction in synaptic plasticity in the hippocampus (Xu et al., 1998). Chronic administration of the tricyclic
antidepressant, imipramine partially reversed the loss in LTP in socially stressed, depressive-like animals (Von Frijtag et al.,. 2001) suggesting imipramine effects on the plasticity phase of neurogenesis. In another animal model of depression, presenting neurogenesis loss and hippocampal volume loss, stressed animals that chronically received the antidepressant, tianeptine, showed similar numbers of dividing cells as control animals (no social stress) a measure of proliferation (Czeh et al . , 2001). In an
experiment looking at association of antidepressants and neurogenesis in normal adult rats, the antidepressant, fluoxetine required chronic administration to cause
proliferation of cells in dentate gyrus (24 hrs post treatment) , but there was considerable loss of nascent PCT PATENT APPLICATION OF KELLEHE - ANDERS SON ET AL . cells whether in the presence or absence of fluoxetine treatment, where fluoxetine provided no observed
differentiation or survival benefit (Malberg et al.,2000) . Results on different neurogenic intervention points by known antidepressants suggest that novel neurogenic agents that intervene at different points in the neurogenesis pathway, could result in potentially diverse therapeutic effects on depression.
These points of intervention can be studied and the target elucidated for novel antidepressant candidates through in vitro assays. Since adult stem cell
proliferation and neurogenesis is observed in adult vertebrates in hippocampal dentate gyrus (Gould et al., 2001; Eriksson et al., 1998), we can use multi-potential hippocampal stem cells to screen agents in vitro for neurogenic activity.
Interestingly, chronic administration of either the antidepressant fluoxetine, an SSRI or the antidepressant rolipram, a phosphodiesterase IV inhibitor, promoted neurogenesis in normal animals (Malberg et al., 2000;
Nakagawa et al., 2002) . One might conclude from these results that any agent that promotes neurogenesis will generate a behavioral benefit in depression, unrelated to PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL . the agents mechanism-of-action or possibly 'there is a common pathway where both drug actions overlap. D' Sa and Duman (2002) suggest a scheme whereby the phosphorylation and activation of CREB and the subsequent expression of BDNF are central to the induction of neurogenesis, that culminates in antidepressant behavior. CREB phosphorylation is increased in animals administered■ rolipram chronically (Nakagawa et al., 2002) and antidepressants that either increase Ca2+/CaM-kinases or cAMP could cause the
phosphorylation of CREB in the nucleus (reviewed by D' sa and Duman 2002). They further suggest that the
phosphorylated CREB then binds to CRE binding site to promote the expression of BDNF and bcl—2, that1 appear critical to cell survival and plasticity. Proof of
neurotrophic factor BDNF' s involvement in depression comes from studies showing that antidepressants and
electroconvulsive shock both caused an increase in BDNF levels (Nibuya et al., 1996) and that intrahippocampal injection of BDNF had antidepressant activity in two models of depression (Shirayama et al . , 2002) .
If neurogenesis is critical for antidepressant activity is it also sufficient and is the mechanism by which the neurogenesis occurs or timing of neurogenesis also critical PCT PATENT APPLICATION OF KELLEHER- NDERS SON ET AL . to the therapeutic activity? We can try to answer these questions using novel agents developed through screening paradigms that identify agents that promote the
proliferation and differentiation of endogenous hippocampal stem cells to neurons in vivo if they will be effective antidepressants. Since we have completed the screening of 10,000 small molecule compounds in in vitro models of neurogenesis and shown that our in vitro screen is
predictive of in vivo neurogenic efficacy, we can then test these orally available agents, that promote in vivo
neurogenesis, in models of depression. Rolipram, an
antidepressant that works by increasing cAMP levels and is neurogenic in animals (Nakagawa et al., 2002) was effective in our primary in vitro neurogenesis screen,. This suggests that our primary in vitro screen would include those agents that might promote neurogenesis by targeting the
cA P/pCREB/BDNF pathway. This does not necessarily exclude all other neurogenesis mechanisms for our NSI compounds. If the target of these neurogenic agents are important for behavioral activity where three separate chemically diverse classes showed in vitro assay efficacy differences and that the mechanism for all does not overlap at the point of CREB phosphorylation and BDNF expression then we might expect PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL . very different effects on behavioral activities in
depression models.
Neuropathology associated with key cognitive regions of the Alzheimer's diseased brain have led to therapeutic
strategies that address the neuronal loss, in the hopes of reducing the cognitive decline. One strategy enlists trophic agents, that regulate neuronal function and survival, as AD therapeutics (see Peterson and Gage, 1999) . Problems with systemic administration, side effects and locating trophic- sensitive neurons generated few clinical successes with these therapies. One AD therapeutic, AIT-082, promotes memory enhancement in AD individuals potentially by stimulating endogenous trophic factors (Ritzman and Glasky, 1999;
Rathbone et al., 1999). So the use of agents to promote increased survival and function of the remaining available neurons appears to have some therapeutic value.
Hippocampus is one of the main brain regions where neurogenesis in adult brain has been documented across several vertebrate species, including monkeys and humans (e.g., Gould et al., 2001; Eriksson et al., 1998). In fact, adult
hippocampal neurogenesis contributes functionally to cognitive capacity. Shors et al. (2001) reported that inhibition of PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . neurogenesis in adult rat hippocampus, in the absence of the destruction of existing neurons, caused impaired memory function. Many studies observed that degenerative conditions induced neurogenesis in mature mammalian brains, suggesting the existence of a natural repair pathway by means of
neurogenesis. A focal ischemic model, reversible photothrombic ring stroke, caused increased neurogenesis in rat cortex by 3- 6% (Gu et al . , 2000). Seizures induced by electroconvulsive shock in adult rats increased neurogenesis in dentate gyrus of hippocampus (Scott et al, 2000; Madsen et al, 2000). Also, rats gamma-irradiated to kill mitotic cells in the CNS showed reduced numbers of nascent neurons and reduced LTP in slice cultures. These observations highlight the likelihood that a cellular mechanism for neurogenesis within adult human CNS, especially in hippocampus, does exist both as a normal
physiological process and as a self-repairing pathway.
In adult neurogenesis a decline due to aging is observed (Kuhn et al., 1996), though proof that this age-dependent decline in neurogenesis causes cognitive impairment is still debated. Considerable evidence does exist, indicating that increased neurogenesis reduces age-associated cognitive decline. This is most dramatically observed with the PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . transplantation of human stem cells into aged rats initiating improved water maze learning and retention (Qu et al., 2001). Other data suggests that induction of neurogenesis by diet restriction (Lee et al., 2000) exercise (van Praag et al., 1999) or growth factor addition (Lichtenwalner et al., 2001) improves learning and memory in adult or aged rats. A number of other inducers of neurogenesis have been identified, including anti-depressants (Malberg et al., 2000; Czeh et al., 2001), and nitric oxide donors (Zhang et al., 2001) suggesting the usefulness of neurogenic agents for other diseases
presenting cognitive-deficits, such as stroke and depression. A small molecule that induces hippocampal neurogenesis that is blood brain barrier penetrable would allow for a potentially novel oral therapeutic for Alzheimer's disease.
Other potential AD therapeutics progressing in clinical trials, target neurodegeneration in the hopes of reducing the neuronal loss and cognitive decline. Apoptotic death involving caspase pathways and DNA fragmentation has been measured in in vitro and animal models of AD and in Alzheimer's diseased brain tissue. The extent of apoptosis leading to neuronal loss is of continual debate with most agreeing it has some effect, but that other neuronal death pathways definitely play a role PCT PATENT APPLICATION OF KELLEHE - NDERS SON ET AL .
(see Behl, 2000; Broe efal., 2001; Roth, 2001). Concern that measures of upstream caspase markers in neurons from AD tissue may not proceed to degeneration has been suggested (Raina et al, 2001). In order to screen for a neuroprotectant
therapeutics it is critical, therefore, to measure more than one endpoint of neuronal death and determine at what point an agent may intervene in the death pathway(s). Behl (2000) suggested that AD pathology is most likely a mixture of apoptotic and necrotic pathways and that concentrating
therapeutic discovery using only one pathway may provide inconclusive results. All hits in our neurogenesis models were tested through our secondary apoptosis/necrosis assay to screen for agents that function both as neurogenic and
neuroprotective agents. These agents may improve or reverse the cognitive decline observed in MCI and AD.
RELATED ART
Arsenijevic Y, Villemure JG, Brunet JF, Bloch JJ, Deglon N, Kostic C, Zurn A, Aebischer P. (2001) . Isolation of multipotent neural precursors residing in_ the cortex of the adult human brain. Exp Neurol, vol 170 ( 1 }: 48-62.
Behl C. Apoptosis and Alzheimer's disease. (2000) J
Neural Transm. Vol. 107 ( 11 ): 1325- . PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Bremner, J.D., Narayan, M. , Anderson, E.R., Staib, L.H., Miller, H.L. Charney, D.S. (2000). Hippocampal volume reduction in major depression. Am. J. Psychiatry vol
157 (1) : 115-118.
Brezun, JM and Daszuta, A. (1999) . Depletion in serotonin decreases neurogenesis in the dentate gyrus and the
subventricular zone of adult rats. Neuroscience vol
89(4): 999-1002.
Broe, M, Shepherd, CE, Milward, EA, and Halliday, GM. (2001) Relationship between DNA fragmentation,
morphological changes and neuronal loss in Alzheimer' s disease and dementia with Lewy bodies. Acta Neuropathol . (Berl) Vol. 101 (6) : 616-624.
Calof AL, Chikaraishi DM. (1989) . Analysis of
neurogenesis in a mammalian neuroepithelium: proliferation and differentiation of an olfactory neuron precursor in vitro. Neuron. 3(l):115-27.
Cameron HA, Hazel TG, McKay RD. (1998) . Regulation of neurogenesis by growth factors and neurotransmitters. J. Neurobiol. vol 36 (2) : 287-306.
Coon HG, Curcio F, Sakaguchi K, Brandi ML, Swerdlow RD. (1989) . Cell cultures of neuroblasts from rat olfactory PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . epithelium that show odorant responses. Proc Natl Acad Sci U S A. vol 86(5) : 1703-7.
Coppell, A.L., Pei, Q., Zetterstrom, T.S. (2003) Bi- phasic change in BDNF gene expression following
antidepressant drug treatment. Neuropharmcaology vol
44 (7) : 903-910.
Czeh, B., Michaelis, T . , Watanabe, T., Frahm, J., de Biurrun, G., van Kampen, M . , Bartolomucci , A., and Fuchs E. (2001) . Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianepine. PNAS Vol. 98 (22) : 12796-12801.
D'Sa, C, and Duman, D.C. (2002). Antidepressants and neuroplasticity . Bipolar Disorders vol 4:183-194.
Eriksson PS, Perfilieva E, Bj ork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH . (1998). Neurogenesis in the adult human hippocampus. Nat Med. vol 4 (ll):1313-7.
Falk A, Frisen J. (2002). Amphiregulin is a mitogen for adult neural stem cells. J Neurosci Res. vol 69 ( 6) : 757-62.
Feron F, Mackay-Sim A, Andrieu JL, Matthaei KI, Holley A,
Sicard G. (1999) Stress induces neurogenesis in non- neuronal cell cultures of adult olfactory epithelium.
Neuroscience . vol 88 ( 2 ) : 571-83. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
Goldman SA, Zaremba A, Niedzwiecki D. (1992) . In vitro neurogenesis by neuronal precursor cells derived from the adult songbird brain. J Neurosci. 12 (7 ): 2532-41.
Gould E, Vail N, Wagers M, Gross CG . (2001) Inaugural Article: Adult-generated hippocampal and neocortical neurons in macaques have a transient existence. Proc. Natl. Acad. Sci. USA. vol 98 ( 19 ) : 10910-10917.
Gu W, . Brannstrom T, Wester P. (2000) Cortical
neurogenesis in adult rats after reversible photothrombotic stroke. J Cereb Blood Flow Metab Vol. 20 (8) : 1166-1173.
Hauser KF, Houdi AA, Turbek CS, Elde RP, Maxson W 3rd. (2000). Opioids intrinsically inhibit the genesis of mouse cerebellar granule neuron precursors in vitro: differential impact of mu and delta receptor activation on proliferation and neurite elongation. Eur J Neurosci. vol 12 ( ): 1281-93.
Jelitai M, Schlett K, Varju P, Eisel U, Madarasz E.
(2002) Regulated appearance of NMDA receptor subunits and channel functions during in vitro neuronal differentiation. J Neurobiol. vol 51 ( 1 ): 54-65.
Jin K, Mao XO, Sun Y, Xie L, Greenberg DA. (2002) . Stem cell factor stimulates neurogenesis in vitro and in vivo. J Clin Invest, vol 110 (3) : 311-9. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. (2002) . Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A. vol 99(18): 11946-50.
Kehl LJ, Fairbanks CA, Laughlin TM, Wilcox GL . (1997) . Neurogenesis in postnatal rat spinal cord: a study in primary culture. Science, vol 276 ( 5312 ): 586-9.
Kempermann, G. and Kronenberg, G. (2003) Depressed new neurons—adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry vol 54 (5) : 499-503.
Kempermann, G. and Gage, FH (2002). Genetic determinants of adult hippocampal neurogenesis correlate with
acquisition, but not probe trial performance, in the water maze task. Eur J of Neurosci, 16, 129-36.
Kuhn, H.G., Dickenson-Anson, H. and Gage, F.H. (199.6) Neurogenesis in the dentate gyrus of the adult rat: age- related decrease of neuronal progeneitor proliferation. J. Neurosci. vol 16 (6), pp2027-33.
Lee, A.L., Ogle, W.O., Sapolsky, R.M. (2002) . Stress and depression : possible links to neurons death in the
hippocampus. Bipolar Disord, vol 4 (2) : 117-128. PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Lee, J., Duan, ., Long, J.M., Ingram, D.K., and attson, .P. (2000) Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. J. Mol. Neurosci.. vol.15 (2) , pp 99-108.
Lichtenwalner , R.J., Forbes, M.E., Bennett, S.A., Lynch, CD., Sonntag, W.E., and Riddle, D.R. (2001)
Intracerebroventricular infusion of insulin-like growth factor-1 ameliorates the age-related decline in hippocampal neurogenesis. Neuroscience vol. 107 (4), pp603-613.
Lucassen, P.J., uller, M.B., Holsboer, F., Bauer, J., Holtrop, A., Wouda, J., Hoogendijk, W.J., DeKloet, E.R., Swaab, D.F. (2001). Hippocampal apoptosis in major
depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am. J. Pathol, vol 158 (2) : 453-468.
Ma , Marie D, Li BS, Hu Q, Andreadis JD, Grant GM, Liu QY, Shaffer KM, Chang YH, Zhang L, Pancrazio JJ, Pant HC, Stenger DA, Barker JL. (2000) . Acetylcholine stimulates cortical precursor cell proliferation in vitro via
muscarinic receptor activation and MAP kinase
phosphorylation. Eur J Neurosci. vol 12 (4 ): 1227-40. PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Madsen TM, Treschow A, Bengzon J, Bolwig TG, Lindvall 0, Tingstrom A. (2000) Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry Vol.
47(12) : 1043-1049.
Malberg, J.E., Eisch, A. J., Nestler, E.J., and Duman, R.S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci.. vol. 20 (24) : 9104-9110.
Marin N, Romero B., Bosch-Morell F. , Llansola M . , Felipo V., Roma J., and Romero F.J. (2000) D-amyloid-induced activation of caspase-3 in primary cultures of rat neurons. Mech. Ageing and Devi. Vol. 119:63-67.
Mayo W, LeMoal M, Abrous DN. (2001) Pregnenolone sulfate and aging of cognitive functions: behavioral,
neurochemical, and morphological investigations. Horm Behav Vol. vol 40 (2 ): 215-217.
Mervaala, E., Fohr, J., Kononen, M., Valkonen-Korhonen, M., Vainio, P., Partanen, K . , Partanen, J., Tiihonen, J., Viinamaki, H., Karjalainen, A.K., Lehtonen, J. (2000).
Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol. Med. vol 30 ( 1 ): 117-125. PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . urrell W, Bushell GR, Livesey J, McGrath J, MacDonald KP, Bates PR, Mackay-Sim A. (1996) . Neurogenesis in adult human. Neuroreport vol 26; 7 ( 6) : 1189-94.
Nakaga a, S., Kim, J-E, Le R. , Malberg, J.E., Chen, J., Steffen, C, Zhang, Y-J. , Nestler, E.J., Duman, R.S.
(2002). regulation of neurogenesis in adult mouse
hippocampus by cAMP and the cAMP reponse element-binding protein. J. Neurosci. vol 22 ( 9) : 3673-3682.
Nibuya,, M. , Nestker, E, J. , Duman, R.S. (1996). Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat
hippocampus. Neurosci. Lett, vol 267:81-84.
Nestler, E . J. , Barrot, . , DiLeone, R.J., Eisch, A., Gold, S.J., and Monteggia, L.M. (2002). Neurobiology of
Depression. Neuron, vol 34:13-25.
Palmer TD, Markakis EA, Willhoite AR, Safar F, Gage FH . (1999) Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. J Neurosci. vol 19 (19) : 8487-97.
Peterson D.A. and Gage F.H. (1999) Trophic factor therapy for neuronal death. In: Alzheimer Disease, Terry, Katzman, Bick, Sisodia eds 2nd edition. PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Pham, K., Nacher, J., Hof, PR., McEwen, B.S. (2003).
Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult dentate gyrus. Eur. J. Neurosci. vol 17 (2 ): 879-886.
Pincus DW, Harrison-Restelli C, Barry J, Goodman RR, Eraser RA, Nedergaard M, Goldman SA. (1997). In vitro neurogenesis by adult human epileptic temporal neocortex. Clin Neurosurg. vol 44:17-25.
Qu, T, Brannan, C.L., Kim, H.M., and Sugaya, K. (2001) Human neural stem cells improve cognitive function of aged brain. Neuroreport vol. 12 (6), pp. 1127-32.
Raina, AK, Hochman A., Zhu, X., Rottkamp, C.A., Nunomura, A., Siedlak, S.L., Boux, H., Castellani, R.J., Perry, G. , Smith,, M. A. (2001) Abortive apoptosis in Alzheimer's disease. Acta Neuropahtol (Berl) Vol. 101 (4 ): 305-310.
Rathbone MP, Middlemiss PJ, Gysbers J , Andrew C, Herman MA, Reed JK, Ciccarelli R, Di Iorio P, and Caciagli F.
(1999) Trophic effects of purines in neurons and glial cells. Prog. Neurobiol. Vol. 59 ( 6) : 663-90.
Ritzman R, Glasky AJ. (1997) Psychopharmacological actions of AIT-082. Soc. Neurosci. Abs. Vol. 23:1896. PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Rozental R, Mehler MF, Morales M, Andrade-Rozental AF, Kessler JA, Spray DC. (1995) . Differentiation of
hippocampal progenitor cells in vitro: temporal expression of intercellular coupling and voltage- and ligand-gated responses. Dev Biol. 167 ( 1 ): 350-62.
Roth,. K.A. (2001) Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. J.
Neuropathol. Exp. Neurol. Vol. 60 ( 9) : 829-838.
Roy NS, Wang S, Jiang L, Kang J, Benraiss A, Harrison- Restelli C, Fraser RA,Couldwell WT, Kawaguchi A, Okano H, Nedergaard M, Goldman SA. (2000) In vitro neurogenesis by progenitor cells isolated from the adult human
hippocampus. Nat Med. vol 6(3):271-7.
Santarelli, L., Saxe, . , Gross, C, Surget, A.,
Battaglia, F. , Dulawa, S., Weisstaub, . , Lee, J., Duman, R., Arancio, 0., Belzung, C, and Hen, R. (2003).
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science vol 301:805-809.
Sapolsky, R.M. (2000) . The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol. Psychiatry vol 48 ( 8 ) : 775-765. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
Satoh M, Yoshida T. (1997). Promotion of neurogenesis in mouse olfactory neuronal progenitor cells by leukemia inhibitory factor in vitro. Neurosci Lett, vol 225(3) :165- 8.
Scott BW, Wojtowicz JM, Burnham WM. (2000) Neurogenesis in the dentate gyrus of the rat following electroconvulsive shock seizures. Exp Neurol Vol. 165 (2) : 231-236.
Seaberg RM, van der Kooy. (2002) Adult rodent neurogenic regions: the ventricular . subependyma contains neural stem cells, but the dentate gyrus contains restricted progenitors. J Neurosci. vol 22 (5) : 1784-93.
Sheline, Y.I., Wang, P.W., Gado, M.H., Csernansky, J.G., Vannier, M.W. (1996). Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci . USA vol 93:3908- " 3913.
Shingo T, Sorokan ST, Shimazaki T, Weiss S. (2001) .
Erythropoietin regulates the in vitro and in vivo
production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci. vol 21 (24 ): 9733-43.
Shirayama, Y., Chen, A.C.-H., Nakagawa, S., Russell, D.S., Duman, R.S. (2002). Brain-derived neurotrophic factor PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . produces antidepressant effects in behavioral models of depression. J. Neurosci. vol 22 (8) : 3251-3261.
Shors TJ, iesegaes G, . Beylin A, Zhao M, Rydel T, Gould E. (2001) Neurogenesis in the adult is involved in the formation of trace memories. Nature vol 410 ( 6826) : 372-376. Shou J, Rim PC, Calof AL. (1999) . BMPs inhibit neurogenesis by a mechanism involving degradation of a transcription factor. Nat Neurosci. 2(4):301-3.
Takahashi J, Palmer TD, Gage FH. (1999) . Retinoic acid and neurotrophins collaborate to regulate neurogenesis in adult-derived neural stem cell cultures. J Neurobiol. vol 38(1) :65-81.
Taupin P, Ray J, Fischer WH, Suhr ST, Hakansson K, Grubb A, Gage FH. (2000) . FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor. Neuron, vol 28 (2 ): 385-97.
Von Frijtag, J.C., Kamal, A., Reijmers, L.G., Schrama, L.H., van den Bos, R., Spruijt, B. . (2001). Chronic imipramine treatment partially reverses the lnog-term changes of hipocampal synaptic plasticity in socially stressed rats. Neurosci. Lett, vol 309 ( 3 ) : 153-156.
Wohl CA, Weiss S. (1998) . Retinoic acid enhances neuronal proliferation and astroglial differentiation in PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . cultures of CNS stem cell-derived precursors. J Neurobiol. vol 5; 37 (2) :281-90.
Xu, L.., Holscher, C, Anwyl, R. , Rowan, M.J. (1998).
Glucocorticoid receptor and protein/RNA synthesis-dependent mechanisms underlie the control of synaptic plasticity by stress. PNAS USA. vol 95:3204-3208.
Zhang, R. , Zhang, L., Zhang, Z., Wang, Y., Lu, M.,
Lapointe, M., and Chopp, M. (2001) A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann. Neurol, vol. 50 (5), pp 602-11.
SUMMARY OF THE INVENTION
A neurogenic drug is an agent that enhances the process of generating new neurons (neurogenesis) . Recent studies indicate that neurogenesis occurs in the adult human brains under normal as well as under degenerative conditions and that such adult-generated neurons do
contribute functionally to the brain physiology such as learning and memory. These observations highlight the likelihood that a cellular mechanism for neurogenesis within adult human CNS, especially in .hippocampus, does exist both as a normal physiological pathway and as a self- PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . repairing pathway. What is lacking and contributes to permanent damage may be (1) the volume/persistence of neurogenesis and/or (2) the survival/maturation of the new neurons. The objective of the neurogenesis screen as described here is to discover a compound that will
significantly boost either of these processes.
Many neurological diseases, including Alzheimer's disease, mild cognitive impairment, dementia, age-related cognitive decline, stroke, traumatic brain injury, spinal cord injury and the like are neurodegenerative conditions. Neuropsychiatric diseases including depression, anxiety, schizophrenia and the like also show nerve cell
dysfunction leading to cognitive, behavioral, and mood disorders. A neurogenic drug would be beneficial for countering and treating these diseases.
The present invention discloses a method of
discovering such a neurogenic drug. Such drug will serve to prevent or treat neurodegenerative and neuropsychiatric disorders by promoting the birth of new neuron endogenously within the nervous system by administering the compounds of the present invention into the patient. This may involve delivery of the agents alone or together with transplanted stem cells or progenitor cells. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
Using the method herein, compounds of the type, Fused Imidazoles, Aminopyrimidines , Nicotinamides, Aminomethyl Phenoxypiperidines and Aryloxypiperidines are evaluated for their ability to promote neurogenesis by proliferation/ differentiation of human hippocampal multipotent stem/ progenitor cells and neuronal progenitors.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Schematic description of neurogenesis processes captured in the assay and different potential sites of a neurogenic drug action.
Figure 2. Detection of changes in cell number by Alamar Blue dye. Alamar Blue, a fluorescent dye, is used as an indicator of metabolic respiration to determine optimum plating density. Results at an initial plating density of 30,000 cells/well suggest a large difference in cell number on removal of mitogen from the N2b media
(differentiation) versus N2b with mitogen (proliferation) conditions. This figure only describes total cellular activity, further markers are required to determine what cell types (e.g. neuronal, glial) are observed under differentiating media. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
Figure 3A. Influence of known growth factors on proliferation and neurogenesis relative to control.
Hippocampal progenitor cells were treated for seven days with differentiation media (without mitogen) in the
presence or absence of 20 ng/ml of growth factor dosed every other day. Plates were treated with Alamar Blue as described in Methods, then fixed and stained with antibody (TuJl) against type III beta-tubulin (neuronal marker). The 96-well plate was read in a fluorescent plate reader. Bars represent the Mean+SD from 4 wells per treatment.
Figure 3B. LIF effects on hippocampal cell
proliferation and neurogenesis by manual cell counting. Hippocampal progenitor cells were treated for seven days with differentiation media (without mitogen) in the
presence or absence of 20 ng/ml LIF. Three fields were analyzed per well for total number of cells (DAPI positive nuclei) and for total number of neurons (TUJI positive cells) . Bars represent the Mean+SD from 4 wells per
treatment. The percentage of neurons calculated for each treatment are as follows: 48.5 + 6.3% for controls and 53.6+1.15 for LIF. The non-TUJl positive cells are mainly astrocytic (GFAP+) . PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Figure 4. Examples of proliferation profile of compounds selected from primary screening. Proliferation was measured after compound treatment for 7 days by Alamar Blue staining of live cells per well. Shown are relative values over the vehicle control.
Figure 5. Example of neurogenesis profile of
compounds selected from primary screening. After 7 days of compound treatment, the ratio of neuron number (TuJl stained) to the total nuclei number (Hoechst stained) was determined. Shown are the relative ratio of neuron: total cells for each compound over the vehicle control in
percentage. Typical ratio for vehicle control is 40-50% neurons. The ratio can change by either increased
differentiation of the cells to neurons, decreased
proliferation of astrocytes, or increased proliferation of neuronal progenitors.
Figure 6. Examples of neurogenesis profile of
compounds selected from primary screening. After 7 days of compound treatment, the cells were stained with TuJl for neurons. The absolute number of TuJl+ neurons per area was quantified and expressed as a relative value to the vehicle treated control. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
Figure 7. Dose-dependent increase in neuron number. Differentiating human hippocampal progenitor cells were treated for 7 days with varying concentrations of "primary hits". Subsequently, the cells were fixed, stained with TuJl, and positive cells were quantified by an automated cell counter. Shown are the number of neurons after each treatment normalized against the vehicle control (0 microM =1.0) .
DETAILED DESCRIPTION OF THE INVENTION
1. A Stable Cell Line of Neural Progenitors
A screening of a large number of unknown agents (e.g., protein factors, peptides, nucleic acids, natural
compounds, or synthetic compounds) for discovering a candidate drug involves repeating the same test for several hundreds to several million times. This requires a great deal of reproducibility from the test. ' In order to obtain such reproducibility for neurogenesis assay, we have created stable cell lines of neural progenitors, which upon differentiation generate reproducible quantities of
neurons. In a preferred embodiment, a multipotent neural stem/progenitor cell line derived from human hippocampus PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . was used. Cell lines derived from other CNS areas, including dentate gyrus of an adult brain, can also
substitute. A neural progenitor population derived as a stable cell line from partial differentiation of embryonic stem cells can also be used. For this purpose, a cell line is defined as a population of cells having been expanded for at least 10 cell-doublings.
Cell lines that are genetically engineered to enhance the cells' mitotic capacity can also be used. In a
preferred embodiment, the genetic modification consists of over-expression of functional c-myc protein intracellularly under a conditional activation system such as c-myc protein fused to a ligand-binding domain of an estrogen receptor. Cell lines that are not genetically engineered are
preferred and can also be used.
In a preferred embodiment, a progenitor population that upon differentiation generates both neurons and glia in a single culture has been used. Presence of glia, either astrocytes and/or oligodendrocytes or their
precursors, are required to promote physiological
maturation of nascent neurons born from their precursors in culture . PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
In a preferred embodiment, differentiation of the progenitors is initiated by withdrawing the mitogen from the culture. Serum as well as other growth-promoting factors should be avoided from the differentiating culture since they will significantly affect the reproducibility and interfere with the neurogenesis assay.
2. Preparation of Assay Plate
Neural stem/progenitor cells differentiate
spontaneously in the absence of a mitogen.
Undifferentiated mitotic cells are harvested by enzyme treatment to remove residual mitogen, in the preferred embodiment, basic fibroblast growth factor (bFGF) . The collected cells are seeded into appropriate plates
(standard 96-well or 384-well) pre-coated with the usual extra cellular matrix proteins (poly-D-lysine and
fibronectin, for example) for attachment of the cells. The initial seeding density can be within the range of about 2,000-125,000 cells per well of a 96-well plate. The preferred density is 40,000 cells per well of a 96-well plate, which has been optimized for best signal-to-noise ratio. Too low cell density retards the initiation of differentiation and results in poor plating efficiency, PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . which interferes with the assay. Too high cell density leads to inhibition of neurogenesis due to cell-cell contact and paracrine factors, which also interferes with the assay. The actual cell number can be proportionally decreased or increased depending upon the surface area of the culture substrate used. For example, for a 384-well plate, which has approximately 1/4 of the surface area of a 96-well plate, the initial seeding density should be decreased accordingly (1/4).
3. Detection of Neurogenesis
The key activity of a neurogenic drug is to increase the number of neurons generated from their precursors. A molecule can bring about such increase in the neurogenesis by a number of different mechanisms. It can act as a mitogen for the neural stem/progenitor cells and increase the progenitor's cell number, which in turn results in increased number of neurons in the culture when
differentiated. Or, it can act as a neuronal specification factor by promoting the stem/progenitor cell
differentiation toward neurons in the expense of glia.
This will also result in increased number of neurons in the culture, but without changing the overall cell number. Or, PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . it can act as a mitogen for committed neuronal progenitors that differentiate only into neurons. Increasing this subpopulation would also increase the final number of neurons in the culture. Or, it can act as a survival factor to rescue immature neurons from undergoing cell death during differentiation, which will result in
increased neurons (Figure 1).
The assay method here captures all of these
possibilities by allowing for sufficient time for these processes to unfold. In a preferred embodiment, for human neural stem/progenitor cells, the assay is continued for seven days. A minimum of three days from the onset of differentiation should be allowed for stable expression of definitive neuronal markers to appear. A sufficient time is also required for a compound action on differentiation and/or proliferation to take place to a sufficient degree to be reliably detectable. Manifestation of drug-induced changes in neuron number takes a minimum of three days for the human cells to be detectable.
The final neuron number is detected by immunostaining of the culture with antibodies against neurons and
quantified by counting of the immunopositive neurons and/or by measuring the staining intensity. PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Method for Measuring Neurogenesis
(1) Undifferentiated human neural stem/progenitor cells were harvested by enzyme treatment.
(2) The collected cells were seeded at 40,000 cells per well of 96-well plates pre-coated with extracellular matrix proteins (e.g., Biocoat PDL, Fisher). The seeding media is a standard serum-free, growth factor- free, basal media that supports healthy neuronal/glial survival, such as N2 without phenol red.
(3) Test agents at appropriate concentrations were added to each well on Day 0.
(4) The assay plates were incubated for 7 days, with 50% media change at every other day. On Day 2, 4,· and 6 of post-plating, additional increment of the screening agents at appropriate concentrations were added to each well.
(5) On the final day of the culture (Day 7), alamar blue dye was added to each well and the cultures were further incubated for 2 hours at 37°C.
(6) The fluorescence of the oxidized dye in each well was read by a fluorescent plate reader with the following settings: PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
Read Mode End Point
Excitation 530nm, emission 590nm, cutoff 570nm The fluorescence level is proportional to the number of respiring cells in the culture and is a measure of a proliferative activity of a test agent (Figure 2) .
(7) After the alamar blue assay, the cells were fixed and stained with antibodies against neuron-specific antigens according to standard procedures. Typical antigens effective were Typelll-beta tubulin and
MAP2c.
(8) The total cell number in each well was quantified by staining the cultures with a nuclear dye such as DAPI or Hoechst according to standard procedures.
(9) As a preliminary detection of positive activities, the overall immunostaining intensity in each well was read by a fluorescence plate reader. For the positive
-hits, more quantitative analysis was carried out by automated morphometric counting of individual cells^
5. Examples
Example 1. Selection of a positive control. Several neurotrophic factors--including brain-derived neurotrophic factor, glia-derived neurotrophic factor, neurotrophic PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL . factor-3, and leukemia inhibitory factor--suggested to have neurogenic properties were tested in the assay described above. Only one (leukemia inhibitory factor) was effective (Figure 3A and 3B) . Thus, the assay can discriminate test agents for selectively having a neurogenic activity. The positive control utilized is leukemia inhibitory factor (LIF) , a cytokine growth factor, at 20 ng/ml. The selection of LIF as the positive control is based on its properties to increase by 2-3 fold the number of neurons and glia. This effect validates both the neural stem cell system, in which, should a compound be effective in neurogenesis, the cells respond appropriately by enhanced differentiation and/or mitosis, and the assay method in which such cellular responses can be measured reproducibly and quantifiably . Example 2. Primary screening of unknown compounds.
5,628 synthetic compounds of the type Fused
Imidazoles, Aminopyrimidines , Nicotinamides, Aminomethyl Phenoxypiperidines and Aryloxypiperidines are evaluated for their effect on neurogenesis according the assay method described above. From the preliminary analysis using the fluorescent plate reader, over 300 compounds to date showed initial positive activity. Those were re-analyzed by quantitative neuron counting. Among them, 30 compounds PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . significantly increased cell number '( "proliferation" ,
Figure 4); 53 increased the number of neurons
("neurogenesis", Figure 5 & Figure 6); and 7 showed
significant activity in both. The significance level was empirically set at an activity above 30% change over the vehicle control for proliferation and above 10% change for neurogenesis. A summary of the result in the compound screening is provided in Table I.
Table I. Summary of Compound Screening
Figure imgf000041_0001
Example 3. Dose-response profiles.
Linearity of dose-response and in vitro neurotoxicity are used to further filter down desired compounds from the primary screen. The dose-response curve measures
neurogenesis over a concentration range of lOOpicaM to lOOmicroM. The rationale for this is to eliminate early on those compounds with pronounced toxicity and those without a dose-dependent effect on neurogenesis. Examples of several primary hits fully analyzed for dose-response are PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . shown in Figure 7. Significantly, most compounds exhibit a linear response over several log concentrations below
ImicroM. This indicates that the assay for primary
screening is reliable and that the quality of the compound library is high. Table II contains the summary of EC50 of each compound tested. On the other hand, at high
'concentrations (100 microM) , some, but not all showed high level of neurotoxicity, indicating that analyzing dose- response curves will be discriminatory and. serve as an effective early filter.
Table II. Activity Profile of Primary Hits in Vitro
Figure imgf000042_0001
PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
UTILITIES OF THE INVENTION
In one aspect of this invention an agent would be administered to treat a neurodegenerative disease. In a preferred embodiment of this invention the
neurodegenerative disease would be Alzheimer's disease, dementia, mild cognitive impairment, aged-related cognitive decline, Parkinson's disease, amyotrophic lateral
sclerosis, multiple sclerosis, demyelination, stroke, spinal injuries, traumatic injuries, neuropathic pain, and the like.
In another of its aspects, this invention the agent would be administered to treat a psychiatric disease. In a preferred embodiment of this invention the psychiatric disease is depression, post-traumatic stress syndrome, stress, anxiety, schizophrenia, sleep deprivation, cogntive dysfunction, amnesia, and the like.
In another aspect of the invention an agent would be administered by any number of routes and multipotent stem cells or differentiated multipotent stem cells would be transplanted into brain. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
In another aspect of the invention the structures of the formula are utilized in above methods:
Structure Formula 1: fused imidazoles
Figure imgf000044_0001
Structure Formula 2: aminopyrimidines
Figure imgf000044_0002
Structure Formula 3: nicotinamides
Figure imgf000044_0003
NH PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
Structure Formula 4: aminomethyl phenoxypiperidines
Figure imgf000045_0001
While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments, but on the contrary is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
Thus, it is to be understood that variations in the present invention can be made without departing from the novel aspects of this invention as defined in the claims. PCT PATENT APPLICATION OF KELLEHER- ANDERS SON ET AL .
All patents and articles cited herein are hereby incorporated by reference in their entirety and relied upon .

Claims

PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL . CLAIMS What is claimed is:
1. A method of selecting a neurogenic agent, comprising the steps of:
(a) obtaining a stable neural progenitor cell line;
(b) plating undifferentiated neural progenitor cells into an assay plate;
(c) culturing the neural progenitor cells in a serum- free, mitogen-free medium;
(d) exposing the neural progenitor cells to a test agent; and
(e) measuring a change in the number of neurons.
2. The method of claim 1, wherein the neural progenitor cell line is derived from mammalian' CNS .
3. The method of claim 1, wherein the neural progenitor cell line is derived from human CNS.
4. The method of claim 1, wherein the neural progenitor cell line is derived from human hippocampus.
5. The method of claim 1, wherein the neural progenitor cell line is derived from human subventricular zone.
6. The method of claim 1, wherein the neural progenitor cell line is derived from mammalian pluripotent or totipotent stem cells. PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
7. The method of claim 1, wherein the neural progenitor cell line is capable of differentiating into neurons and glia.
8. The method of claim 1, wherein the neural progenitor cell line is capable of differentiating into neurons.
9. The method of claim 1, wherein the test agent is a fused imidazole, as described in Structure Formula 1.
10. The method of claim 1, wherein the test agent is a aminopyrimidine, as described in Structure Formula 2.
11. The method of claim 1, wherein the test agent is a nicotinamide, as described in Structure Formula 3.
12. The method of claim 1, wherein the test agent is an aminomethyl phenoxypiperidine , as described in Structure Formula 4.
13. The method of claim 1, wherein the test agent is an aryloxypiperidine, as described in Structure Formula 5.
14. A method for treating neurodegenerative and
neuropsychiatric disorders comprising the step of
administering a fused imidazole, as described in Structure Formula 1, to a patient in need thereof.
15. A method for treating neurodegenerative and
neuropsychiatric disorders comprising the step of PCT PATENT APPLICATION OF KELLEHER-ANDERSSON ET AL .
•administering an aminopyrimidine , as described in Structure Formula 2, to a patient in need thereof.
16. A method for treating neurodegenerative and
neuropsychiatric disorders comprising the step of
administering a nicotinamide, as described in Structure Formula 3, to a patient in need thereof.
17. A method for treating neurodegenerative and
neuropsychiatric disorders comprising the step of
administering an aminomethyl phenoxypiperidine , as
described in Structure Formula 4, to a patient in need thereof.
18. A method for treating neurodegenerative and
neuropsychiatric disorders comprising the step of
administering an aryloxypiperidine , as described in
Structure Formula 5, to a patient in need thereof.
PCT/US2003/038670 2002-12-09 2003-12-05 Method for discovering neurogenic agents WO2004053071A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003293409A AU2003293409A1 (en) 2002-12-09 2003-12-05 Method for discovering neurogenic agents
EP03790356A EP1576134B1 (en) 2002-12-09 2003-12-05 Method for discovering neurogenic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43235902P 2002-12-09 2002-12-09
US60/432,359 2002-12-09
US49367403P 2003-08-08 2003-08-08
US60/493,674 2003-08-08

Publications (3)

Publication Number Publication Date
WO2004053071A2 WO2004053071A2 (en) 2004-06-24
WO2004053071A3 WO2004053071A3 (en) 2006-03-30
WO2004053071A9 true WO2004053071A9 (en) 2012-08-16

Family

ID=40846261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038670 WO2004053071A2 (en) 2002-12-09 2003-12-05 Method for discovering neurogenic agents

Country Status (4)

Country Link
US (8) US20040185429A1 (en)
EP (1) EP1576134B1 (en)
AU (1) AU2003293409A1 (en)
WO (1) WO2004053071A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
AU2003293409A1 (en) 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
DK1645626T3 (en) * 2004-09-30 2008-01-21 Reneuron Ltd cell Line
WO2007008758A2 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
JP2009536667A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド 5HT receptor-mediated neurogenesis
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
CA2661232A1 (en) * 2006-08-31 2008-03-06 The University Of Louisville Research Foundation, Inc. Transcription factors for differentiation of adult human olfactory progenitor cells
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2009123877A1 (en) * 2008-03-21 2009-10-08 Braincells, Inc. A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010224485B2 (en) 2009-03-20 2014-04-17 Hg&H Pharmaceuticals (Pty) Ltd Use of pharmaceutical compositions containing mesembrenone
US8980338B2 (en) 2009-03-20 2015-03-17 H.L. Hall & Sons Limited Sceletium extract and uses thereof
BR112012004161B1 (en) * 2009-08-24 2020-04-07 Neuralstem Inc method for synthesizing a neurostimulatory piperazine
US20130210000A1 (en) * 2011-08-19 2013-08-15 Irina Aizman Neurogenic and gliogenic factors and assays therefor
EP2751095B1 (en) 2011-08-29 2021-10-27 Sanford-Burnham Medical Research Institute Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
AU2015277406B2 (en) * 2014-06-16 2019-09-19 Neuralstem, Inc. Protocols for treatment of major depressive disorder (MDD)
JP7204640B2 (en) * 2016-09-12 2023-01-16 ニューラルステム・インコーポレーテッド Improvement of neuropathy associated with diabetes
WO2018075667A1 (en) * 2016-10-18 2018-04-26 Neuralstem, Inc. Amelioration of radiation-induced cognitive dysfunction
US10413534B2 (en) 2017-02-13 2019-09-17 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
US20210106579A1 (en) * 2018-05-17 2021-04-15 Neuralstem, Inc. Amelioration of cognitive and motor deficits associated with alzheimer's
BR112023025330A2 (en) 2021-06-03 2024-02-27 Alto Neuroscience Inc METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH WEAK COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM BENZYLPIPERAZINE-AMINOPYRIDINE AGENT

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US4753635A (en) * 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
NZ226750A (en) 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
EP0380646B1 (en) * 1988-08-04 1999-01-20 Amrad Corporation Limited Use of leukaemia inhibitory factor (lif) for the (in vitro) propagation of embryonic stem cells
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4980174A (en) * 1988-12-23 1990-12-25 Jacqueline Sagen Method for alleviating depression
AU6174490A (en) 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
WO1991009936A1 (en) 1989-12-26 1991-07-11 Hana Biologics, Inc. Proliferated neuron progenitor cell product and process
US5411883A (en) * 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
US5196315A (en) 1990-05-01 1993-03-23 The Johns Hopkins University Human neuronal cell line
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5085670A (en) * 1990-09-17 1992-02-04 The Dow Chemical Company Production of potassium chloride crystals
US6497872B1 (en) * 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
AU665012B2 (en) 1991-07-08 1995-12-14 Neurospheres Holdings Ltd Novel growth factor-responsive progenitor cells which can be proliferated (in vitro)
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5175103A (en) * 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
WO1993009802A2 (en) 1991-11-22 1993-05-27 Genentech, Inc. Tgf-beta to improve neural outcome
NZ256154A (en) 1992-07-27 1997-02-24 California Inst Of Techn Production of mammalian multipotent neural stem cells, antibodies
US5849553A (en) * 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
US5672499A (en) * 1992-07-27 1997-09-30 California Institute Of Technology Immoralized neural crest stem cells and methods of making
US5589376A (en) * 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
AU4995193A (en) 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
AU4950393A (en) 1992-08-19 1994-03-15 Richard Kroczek Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family
PT669973E (en) 1992-10-28 2003-06-30 Neurospheres Holdings Ltd BIOLOGICAL FACTORS AND NEURAL ESTAMINAL CELLS
DE69431993T2 (en) 1993-11-09 2003-11-27 Neurospheres Holding Ltd IN SITU MODIFICATION AND MANIPULATION OF STEM CELLS OF THE CENTRAL NERVOUS SYSTEM
EP0783693B1 (en) 1994-09-23 2001-11-07 Neurospheres Holdings Ltd. In vitro models of cns function and dysfunction
CN1170435A (en) 1994-11-14 1998-01-14 纽罗斯菲里斯控股有限公司 Regulation of neural stem cell proliferation
US5753505A (en) * 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US5770414A (en) * 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
JP3467154B2 (en) * 1996-10-14 2003-11-17 パロマ工業株式会社 Absorption air conditioner
CA2275933A1 (en) * 1996-12-24 1998-07-02 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having nos inhibiting action
WO1998048001A1 (en) 1997-04-24 1998-10-29 California Institute Of Technology Methods for differentiating neural stem cells
CA2294737A1 (en) 1997-07-04 1999-01-14 University Of Utah Research Foundation Neuron-restricted precursor cells
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US5928847A (en) * 1998-03-13 1999-07-27 Eastman Kodak Company Photographic element having ultrathin tabular grains
WO2000009676A2 (en) * 1998-08-14 2000-02-24 California Institute Of Technology Methods of forming neurons
US6284539B1 (en) * 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US20030003572A1 (en) * 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6531464B1 (en) * 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
KR100903755B1 (en) * 2000-05-17 2009-06-18 제론 코포레이션 Neural progenitor cell populations
HN2001000224A (en) * 2000-10-19 2002-06-13 Pfizer IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI - INFLAMMATORY AND ANALGESIC AGENTS.
US20020091133A1 (en) * 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
ES2274973T3 (en) * 2001-04-23 2007-06-01 The Trustees Of The University Of Pennsylvania INHIBITORS OF THE AGGREGATION OF AMYLOID PLATES AND AGENTS FOR OBTAINING DIAGNOSTIC IMAGES.
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
CN1665789A (en) * 2002-06-28 2005-09-07 山之内制药株式会社 Diaminopyrimidinecarboxa mide derivative
AU2003293409A1 (en) 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents

Also Published As

Publication number Publication date
US20100034784A1 (en) 2010-02-11
US20120027733A1 (en) 2012-02-02
EP1576134A2 (en) 2005-09-21
AU2003293409A8 (en) 2004-06-30
US20110135612A1 (en) 2011-06-09
AU2003293409A1 (en) 2004-06-30
EP1576134B1 (en) 2013-03-06
WO2004053071A3 (en) 2006-03-30
US8030492B2 (en) 2011-10-04
US20110052552A1 (en) 2011-03-03
US20140147424A1 (en) 2014-05-29
US8058434B2 (en) 2011-11-15
US20040185429A1 (en) 2004-09-23
US7560553B1 (en) 2009-07-14
US20130195816A1 (en) 2013-08-01
US8674098B2 (en) 2014-03-18
US8362262B2 (en) 2013-01-29
EP1576134A4 (en) 2007-05-30
US8846914B2 (en) 2014-09-30
WO2004053071A2 (en) 2004-06-24
US7858628B2 (en) 2010-12-28

Similar Documents

Publication Publication Date Title
EP1576134B1 (en) Method for discovering neurogenic agents
TWI269812B (en) Therapeutic use of selective PDE10 inhibitors
CA2174098C (en) Method of inducing and maintaining neuronal cells
Kazi et al. PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts
Schnitzler et al. BMP9 (bone morphogenetic protein 9) induces NGF as an autocrine/paracrine cholinergic trophic factor in developing basal forebrain neurons
Gerace et al. PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca2+-permeable AMPA receptors
US7132287B2 (en) Method for neural stem cell differentiation using 5HT-1A agonists
Uliassi et al. A focused library of psychotropic analogues with neuroprotective and neuroregenerative potential
KR20200051585A (en) Pentacyclic compounds
US20130045487A1 (en) Method for discovering neurogenic agents
Grison et al. Ablation of cdk4 and cdk6 affects proliferation of basal progenitor cells in the developing dorsal and ventral forebrain
JP2012524097A (en) Method for reducing pro-ADAM10 secretase and / or beta-secretase levels
Castillo et al. Glutamate differently modulates excitatory and inhibitory adenosine receptors in neuronal and glial cells
TWI486341B (en) Methods and compositions for inhibition of atr and fancd2 activation
Qin et al. NADPH oxidase and endoplasmic reticulum stress is associated with neuronal degeneration in orbitofrontal cortex of individuals with alcohol use disorder
Kanungo et al. Zebrafish Rohon-Beard neuron development: cdk5 in the midst
US20230014181A1 (en) Culture system and methods for improved modeling of neurological conditions
Alharganee et al. The Impact of Methotrexate on Neural Stem Cells and the Protection Provided by Cells in the Neurogenic Niche
Guan et al. Cytosine arabinoside exposure induced cytotoxic effects and neural tube defects in mice and embryo stem cells
Mullah Comparison of differentiation protocols of SH-SY5Y cells for use as an in vitro model of Alzheimer’s disease
Curtis Metabotropic Glutamate Receptor 5 Negative Allosteric Modulation Effects on Microglia Phenotype
Sturgeon G₂ DNA damage checkpoint: inhibitors and there potential for anticancer treatment
Jansson Neural progenitor cell differentiation and migration
Li The mechanisms of ethanol-induced damage to the developing cerebellum: Effects on the cerebellar granule cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003790356

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003790356

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP